Cargando…

Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions

OBJECTIVE: The research evaluated point-of-care drug interaction resources for scope, completeness, and consistency in drug-ethanol and drug-tobacco content. METHODS: In a cross-sectional analysis, 2 independent reviewers extracted data for 108 clinically relevant interactions using 7 drug informati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beckett, Robert D., Stump, Curtis D., Dyer, Megan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Library Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300238/ https://www.ncbi.nlm.nih.gov/pubmed/30598650 http://dx.doi.org/10.5195/jmla.2019.549

Ejemplares similares

Evaluation of drug information resources for interactions between therapeutic drugs and drugs of abuse
por: Beckett, Robert D., et al.
Publicado: (2020)

Off-label use information in electronic drug information resources
por: Rothgeb, Amanda, et al.
Publicado: (2022)

Tertiary drug information sources for treatment and prevention of COVID-19
por: Beckett, Robert D., et al.
Publicado: (2023)

Evaluation of the experiences and needs of users of a drug information resources website
por: Isenor, Jennifer E., et al.
Publicado: (2020)

Evaluation of adverse drug reaction formatting in drug information databases
por: McConachie, Sean M., et al.
Publicado: (2020)

Evaluation of adverse drug reaction formatting in drug information mobile phone applications
por: McConachie, Sean M., et al.
Publicado: (2022)

An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings
por: Chahal, Harinder Singh, et al.
Publicado: (2019)

Assessing Consistency of Drug-Drug Interaction-Related Information Across Various Drug Information Resources
por: Shariff, Atiqulla, et al.
Publicado: (2021)

Adverse drug reactions in drug information databases: does presentation affect interpretation?
por: McConachie, Sean M., et al.
Publicado: (2020)

Evaluating drug-drug interaction information in NDF-RT and DrugBank
por: Peters, Lee B, et al.
Publicado: (2015)

Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users
por: Hindocha, Chandni, et al.
Publicado: (2017)

The accuracy and completeness of drug information in Google snippet blocks
por: Nguyen, Cambrey
Publicado: (2021)

Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions
por: Rassy, Elie, et al.
Publicado: (2022)

Tobacco, Alcohol, Cannabis, and Other Drug Use in the US Before and During the Early Phase of the COVID-19 Pandemic
por: Compton, Wilson M., et al.
Publicado: (2023)

Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
por: Miller, Jennifer E., et al.
Publicado: (2021)

Indian aspects of drug information resources and impact of drug information centre on community
por: Chauhan, Nitesh, et al.
Publicado: (2013)

Evaluation of Point-of-Care Resources for Dietary Supplement Information
por: Montgomery, Ashley E., et al.
Publicado: (2018)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Spending on and Use of Clinician-Administered Drugs in Medicare
por: Hyland, Megan F., et al.
Publicado: (2023)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Similarity and consistency assessment of three major online drug–drug interaction resources
por: Kontsioti, Elpida, et al.
Publicado: (2022)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study
por: Teklay, Gebrehiwot, et al.
Publicado: (2014)

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
por: Long, Aaron S., et al.
Publicado: (2021)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Shared Decision-Making for Drug-Drug Interactions: Formative Evaluation of an Anticoagulant Drug Interaction
por: Gomez Lumbreras, Ainhoa, et al.
Publicado: (2022)

Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis()()
por: Zhao, Jun, et al.
Publicado: (2019)

A Minimal Information Model for Potential Drug-Drug Interactions
por: Hochheiser, Harry, et al.
Publicado: (2021)

Drug interaction resources: mind the gaps
por: Grannell, Louise
Publicado: (2020)

DOAC drug interactions management resource
por: Chadha, Ayush, et al.
Publicado: (2022)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Multicenter randomized comparative trial of Micromedex, Micromedex with Watson, or Google to answer drug information questions
por: Giuliano, Christopher, et al.
Publicado: (2021)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions
por: Tranvåg, Eirik Joakim, et al.
Publicado: (2022)

Evaluation of Drug Labels Following the 2015 Pregnancy and Lactation Labeling Rule
por: Byrne, John J., et al.
Publicado: (2020)

Designing and evaluating contextualized drug–drug interaction algorithms
por: Chou, Eric, et al.
Publicado: (2021)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants
por: Chahal, Harinder Singh, et al.
Publicado: (2021)

How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration’s Modified Risk Tobacco Product Order for IQOS
por: Robichaud, Meagan O, et al.
Publicado: (2023)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_041hjmnspqjdfkhbonopfqndhg